Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir

Journal of Viral Hepatitis

Volumn 21, Issue 4, 2014, Pages 260-263

  Boglione, L ^a   De Nicolo A ^a   Cusato, J ^a   Cariti, G ^a   Di Perri, G ^a   D'Avolio, A ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

anaemia; HCV 1; ribavirin; telaprevir; therapeutic drug monitoring

Indexed keywords

GENOMIC DNA; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETREATMENT; TREATMENT DURATION;

ANAEMIA; HCV-1; RIBAVIRIN; TELAPREVIR; THERAPEUTIC DRUG MONITORING;

ADULT; ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; PYROPHOSPHATASES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84895809467     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12170     Document Type: Article

References (8)

1. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
2. De Franceschi L, Fattovich G, Turrini F, et al,. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31 (4): 997-1004.
3. De Nicolò A, Cusato J, Boglione L, et al,. P-21 Early ribavirin plasma concentrations as predictor of anemia onset after one month of anti-HCV therapy in ITPA stratified population. Rev Antiv Ther Infect dis 2013; 3: 51.
4. D'Avolio A, Ciancio A, Siccardi M, et al,. Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. Ther Drug Monit 2012; 34 (2): 165-170.
5. Hammond K, Jimmerson L, MacBrayne C, et al,. PP-02 Increased plasma and intracellular ribavirin concentrations associated with telaprevir use. Rev Antiv Ther Infect dis 2013; 3: 26.
6. D'Avolio A, Ibanez A, Sciandra M, et al,. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 835 (1-2): 127-130.
7. Reesink HW, Zeuzem S, Weegink CJ, et al,. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131 (4): 997-1002.
8. Hezode C, Forestier N, Dusheiko G, et al,. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360 (18): 1839-1850.